Healwell AI (AIDX) Stock Overview
Operates as a healthcare technology company in Canada, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
AIDX Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Healwell AI Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.76 |
| 52 Week High | CA$1.64 |
| 52 Week Low | CA$0.58 |
| Beta | -0.96 |
| 1 Month Change | -12.64% |
| 3 Month Change | -8.43% |
| 1 Year Change | -45.71% |
| 3 Year Change | 322.22% |
| 5 Year Change | -72.95% |
| Change since IPO | -83.19% |
Recent News & Updates
Narrative Update • Jun 26
AIDX: Future Clinical Adoption And Margin Gains Will Support Upside Potential
Analysts have trimmed their fair value estimate and price target for Healwell AI to CA$2.40 from CA$2.85, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E. Analyst Commentary Recent Street research on Healwell AI reflects a mix of optimism around long term growth potential and caution around execution and valuation, which helps explain the updated fair value estimate and price target.
Narrative Update • Jun 12
AIDX: Future Health System Contracts Will Support AI Deployment Execution
Healwell AI's analyst price targets have been trimmed by up to CA$0.60 in recent reports, with analysts pointing to updated assumptions around revenue growth, margins, discount rate and future P/E expectations as key drivers of the shift. Analyst Commentary Recent Street research on Healwell AI has been mixed, with some firms initiating coverage on a positive footing while others have trimmed their price targets.
Narrative Update • May 29
AIDX: Expanded Real World Evidence And HIE Wins Will Support Long Term Upside
Analysts have trimmed their CA$ price target on Healwell AI, reducing fair value from about CA$4.31 to CA$3.00. They cite more moderate revenue growth, lower profit margins, and a higher assumed P/E multiple as the key factors, while still pointing to supportive initiation and coverage updates from several firms.Recent updates
Narrative Update • Jun 26
AIDX: Future Clinical Adoption And Margin Gains Will Support Upside Potential
Analysts have trimmed their fair value estimate and price target for Healwell AI to CA$2.40 from CA$2.85, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E. Analyst Commentary Recent Street research on Healwell AI reflects a mix of optimism around long term growth potential and caution around execution and valuation, which helps explain the updated fair value estimate and price target.Narrative Update • Jun 12
AIDX: Future Health System Contracts Will Support AI Deployment Execution
Healwell AI's analyst price targets have been trimmed by up to CA$0.60 in recent reports, with analysts pointing to updated assumptions around revenue growth, margins, discount rate and future P/E expectations as key drivers of the shift. Analyst Commentary Recent Street research on Healwell AI has been mixed, with some firms initiating coverage on a positive footing while others have trimmed their price targets.Narrative Update • May 29
AIDX: Expanded Real World Evidence And HIE Wins Will Support Long Term Upside
Analysts have trimmed their CA$ price target on Healwell AI, reducing fair value from about CA$4.31 to CA$3.00. They cite more moderate revenue growth, lower profit margins, and a higher assumed P/E multiple as the key factors, while still pointing to supportive initiation and coverage updates from several firms.Narrative Update • May 03
AIDX: Health System Contracts And AI Deployments Will Drive Future Upside
Analysts have trimmed their average 12 month price target on Healwell AI by around CA$0.50 to CA$3.10. They cited slightly adjusted expectations for revenue growth, profit margins and a higher assumed future P/E multiple reflected in recent TD Securities, Raymond James, Stifel and Scotiabank research.Narrative Update • Apr 19
AIDX: Recalibrated Expectations Will Support Future Upside From Health System Contracts
Analysts have reduced the average price target on Healwell AI by CA$0.25, citing updated assumptions that include slightly lower revenue growth expectations, a higher projected profit margin and a reduced future P/E multiple, along with recent target reductions from several firms and a new bullish initiation from TD Securities. Analyst Commentary Recent research updates on Healwell AI point to a split view, with some firms taking a more cautious stance on valuation while a new initiation sets a more constructive tone.Narrative Update • Apr 04
AIDX: Expanded Real World Evidence Footprint Will Support Long Term Upside Potential
Analysts have trimmed their average price target on Healwell AI by CA$0.50 to CA$3.10, citing updated assumptions around revenue growth, profit margins, discount rates and future P/E, even though at least one firm maintained a positive rating alongside the lower target. Analyst Commentary Recent research reports show that, even with trimmed price targets, bullish analysts still see room for upside in Healwell AI shares at current levels.Narrative Update • Mar 21
AIDX: Future Margin Gains And New Contracts Will Support Upside Potential
Analysts have trimmed their fair value estimate for Healwell AI to CA$2.85 from CA$3.45. This reflects lower Street price targets, a higher discount rate, more moderate revenue growth assumptions, stronger profit margin expectations, and a reduced future P/E multiple.Narrative Update • Mar 06
AIDX: Recalibrated Expectations Will Support Future Upside From Emerging Health System Contracts
Analysts trimmed their price target on Healwell AI by CA$0.50, citing updated expectations around growth, profitability, and future P/E assumptions reflected in recent research. Analyst Commentary Bearish analysts have reacted to the updated research by trimming their price targets, including a C$0.50 cut that reflects a more cautious stance on Healwell AI's growth trajectory, profitability path, and future P/E assumptions.Narrative Update • Feb 20
AIDX: WELLTRUST Launch Will Support Recalibrated Expectations And Higher Future P/E
Analysts have trimmed their 12 month price target on Healwell AI by CA$0.50, citing updated expectations for revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Bearish analysts trimming their 12 month price targets by CA$0.50 are signaling a more cautious stance on Healwell AI, especially around how future growth and profitability might justify current valuations.Analysis Article • Feb 11
Why We're Not Concerned Yet About Healwell AI Inc.'s (TSE:AIDX) 26% Share Price Plunge
To the annoyance of some shareholders, Healwell AI Inc. ( TSE:AIDX ) shares are down a considerable 26% in the last...Narrative Update • Feb 05
AIDX: Second Profitable Quarter Will Support Recalibrated Expectations And Higher Future P/E
Narrative Update on Healwell AI Analysts have trimmed their price targets on Healwell AI by about C$0.50 to around C$2.25. They point to updated estimates that reflect slightly lower projected growth, a modestly higher discount rate, and a recalibration of assumed future P/E multiples following recent quarterly results.Analysis Article • Nov 21
Why We're Not Concerned Yet About Healwell AI Inc.'s (TSE:AIDX) 30% Share Price Plunge
The Healwell AI Inc. ( TSE:AIDX ) share price has fared very poorly over the last month, falling by a substantial 30...Analysis Article • Nov 09
Analysts Are Updating Their Healwell AI Inc. (TSE:AIDX) Estimates After Its Third-Quarter Results
There's been a notable change in appetite for Healwell AI Inc. ( TSE:AIDX ) shares in the week since its quarterly...Analysis Article • Nov 06
Healwell AI Inc. (TSE:AIDX) Analysts Are Reducing Their Forecasts For This Year
Market forces rained on the parade of Healwell AI Inc. ( TSE:AIDX ) shareholders today, when the analysts downgraded...Analysis Article • Aug 14
A Look At The Intrinsic Value Of Healwell AI Inc. (TSE:AIDX)
TSX:AIDX 1 Year Share Price vs Fair Value Explore Healwell AI's Fair Values from the Community and select yours Key...New Narrative • May 18
Acquisition Will Create A Unified Global Healthcare Platform
The acquisition of Orion Health is expected to boost Healwell AI's international presence and revenue growth through enhanced data infrastructure and operational synergies.Analysis Article • Apr 19
Healwell AI Inc.'s (TSE:AIDX) Stock Retreats 25% But Revenues Haven't Escaped The Attention Of Investors
Healwell AI Inc. ( TSE:AIDX ) shareholders that were waiting for something to happen have been dealt a blow with a 25...Analysis Article • Jan 14
Healwell AI Inc. (TSE:AIDX) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Healwell AI Inc. ( TSE:AIDX ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...Analysis Article • Nov 25
Investors Appear Satisfied With Healwell AI Inc.'s (TSE:AIDX) Prospects As Shares Rocket 34%
Healwell AI Inc. ( TSE:AIDX ) shareholders are no doubt pleased to see that the share price has bounced 34% in the last...Analysis Article • Nov 03
Is Healwell AI (TSE:AIDX) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Sep 10
Why Investors Shouldn't Be Surprised By Healwell AI Inc.'s (TSE:AIDX) P/S
When close to half the companies in the Healthcare industry in Canada have price-to-sales ratios (or "P/S") below 0.8x...Analysis Article • Jun 14
Healwell AI Inc.'s (TSE:AIDX) Intrinsic Value Is Potentially 46% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Healwell AI fair value estimate is CA$3.97 Current share price...Analysis Article • Mar 11
Healwell AI Inc. (TSE:AIDX) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Healwell AI Inc. ( TSE:AIDX ) shareholders have had their patience rewarded with a 33% share price jump in the last...Shareholder Returns
| AIDX | CA Healthcare | CA Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 1.0% |
| 1Y | -45.7% | 35.5% | 30.2% |
Return vs Industry: AIDX underperformed the Canadian Healthcare industry which returned 35.5% over the past year.
Return vs Market: AIDX underperformed the Canadian Market which returned 30.2% over the past year.
Price Volatility
| AIDX volatility | |
|---|---|
| AIDX Average Weekly Movement | 6.1% |
| Healthcare Industry Average Movement | 5.2% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.7% |
Stable Share Price: AIDX has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: AIDX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 570 | James Lee | www.healwell.ai |
Healwell AI Inc. operates as a healthcare technology company in Canada, Australia, and New Zealand. The company operates in two segments, AI and Data Sciences, and Healthcare Software. It focuses on developing and commercializing clinical decision support systems to help healthcare providers detect rare and chronic diseases.
Healwell AI Inc. Fundamentals Summary
| AIDX fundamental statistics | |
|---|---|
| Market cap | CA$229.99m |
| Earnings (TTM) | -CA$33.40m |
| Revenue (TTM) | CA$129.03m |
1.8x
P/S Ratio-6.9x
P/E RatioIs AIDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIDX income statement (TTM) | |
|---|---|
| Revenue | CA$129.03m |
| Cost of Revenue | CA$56.67m |
| Gross Profit | CA$72.36m |
| Other Expenses | CA$105.77m |
| Earnings | -CA$33.40m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 56.08% |
| Net Profit Margin | -25.89% |
| Debt/Equity Ratio | 67.2% |
How did AIDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 22:05 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Healwell AI Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kinstlinger | Alliance Global Partners |
| Gabriel Leung | Beacon Securities Limited |
| Douglas Taylor | Canaccord Genuity |